Listed

Marker Therapeutics, Inc.

MRKRNasdaqCIK 1094038HealthcareFiscal year ends Dec 31

Latest reported revenue, Q1 FY2026$751.7kRevenue, Q1 FY2026, three months to 2026-03-31$751.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figureThree months to Mar 31, 2026, from the 10-Q filed May 15, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.09Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure+69.0% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$751.7kOperating margin −541.8%
Diluted EPS−$0.09, Q2 FY2026
Marker Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$k1,926Revenue, Q3 FY2024, three months to 2024-09-30$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure2,252Revenue, Q4 FY2024, three months to 2024-12-31$2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure349Revenue, Q1 FY2025, three months to 2025-03-31$349.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure861Revenue, Q2 FY2025, three months to 2025-06-30$861.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure1,233Revenue, Q3 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure1,103Revenue, Q4 FY2025, three months to 2025-12-31$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure752Revenue, Q1 FY2026, three months to 2026-03-31$751.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figurenot reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)
Operating margin%(124.6%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(171.5%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Revenue: $2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(1420.1%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$5.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Revenue: $349.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(594.8%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$5.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Revenue: $861.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure(173.3%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$2.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(170.7%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$1.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(541.8%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Revenue: $751.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figurenot reported (Revenue not reported)
Net margin%(119.8%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(170.4%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Revenue: $2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(1273.6%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$4.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Revenue: $349.1k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(466.3%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Revenue: $861.2k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-14, accession 0001410578-25-001826.Report this figure(162.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Revenue: $1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figure(154.4%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Revenue: $1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274. Derived: 12-month figure less the 9-month figure.Report this figure(423.0%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Revenue: $751.7k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figurenot reported (Revenue not reported)
Diluted EPS$ per share(0.26)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figurenot reported (Diluted EPS not reported)(0.40)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(0.29)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure(0.12)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-111502.Report this figurenot reported (Diluted EPS not reported)(0.16)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062763.Report this figure(0.09)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097262.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$3.5mOperating margin −363.5%
Diluted EPS−$0.79, FY2025
Marker Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$k0.0Revenue, FY2021, twelve months to 2021-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2022-03-17, accession 0001410578-22-000418.Report this figure3,514Revenue, FY2022, twelve months to 2022-12-31$3.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-26, accession 0001410578-24-000297.Report this figure3,311Revenue, FY2023, twelve months to 2023-12-31$3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure6,591Revenue, FY2024, twelve months to 2024-12-31$6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure3,547Revenue, FY2025, twelve months to 2025-12-31$3.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)(563.3%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$19.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-26, accession 0001410578-24-000297.Revenue: $3.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-26, accession 0001410578-24-000297.Report this figure(440.4%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$14.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000549.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure(168.7%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$11.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274.Revenue: $6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure(363.5%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274.Revenue: $3.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure
Net margin%not reported (Revenue of zero not reported)(851.9%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$29.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-26, accession 0001410578-24-000297.Revenue: $3.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-03-26, accession 0001410578-24-000297.Report this figure(248.8%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001410578-25-000549.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure(162.8%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$10.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274.Revenue: $6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure(343.0%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$12.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001104659-26-031274.Revenue: $3.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure
Diluted EPS$ per share(5.47)Diluted EPS, FY2021, twelve months to 2021-12-31−$5.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-22, accession 0001410578-23-000324.Report this figure(3.58)Diluted EPS, FY2022, twelve months to 2022-12-31−$3.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-26, accession 0001410578-24-000297.Report this figure(0.94)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-31, accession 0001410578-25-000549.Report this figure(1.19)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure(0.79)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-18, accession 0001104659-26-031274.Report this figure
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Marker Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
NEA Management Company, LLC2026-06-30$2.4m1,625,678Unchanged
Blue Owl Capital Holdings LP2026-06-30$814.7k554,250Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$626.5k426,169Added+36,850
Aisling Capital Management LP2026-06-30$478.3k325,370Unchanged
RENAISSANCE TECHNOLOGIES LLC2026-06-30$366.7k249,423Added+74,129
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$205.6k139,816Reduced−21,094
OSAIC HOLDINGS, INC.2026-06-30$165.6k112,649Added+19,528
VANGUARD FIDUCIARY TRUST CO2026-06-30$128.3k87,269Unchanged
LPL Financial LLC2026-06-30$122.2k83,147Added+100
Concurrent Investment Advisors, LLC2026-06-30$99.9k67,963New+67,963

Recent filings

All 700 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Marker Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-1911:12 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001104659-26-116720
2026-08-1420:35 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-097262
2026-05-1521:00 ET10-QQuarterly reportPeriod 2026-03-310001104659-26-062763
2026-05-0420:30 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-26-054940
2026-03-2020:05 ETDEF 14AProxy statementPeriod 2026-05-010001104659-26-032694
2026-03-1921:36 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-031309
2026-03-1821:26 ET10-KAnnual reportPeriod 2025-12-310001104659-26-031274
2026-02-0921:06 ET8-K5.08 Item not in the standard list; 9.01 Financial statements and exhibits0001104659-26-012063
2025-11-1721:22 ETSCHEDULE 13D/AOwnership report, active investor, amended0001072613-25-000858
2025-11-1412:20 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-25-111940

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 18, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1094038
Tickers
MRKR
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
TAPIMMUNE INC. (to 2018-10-17); TAPIMMUNE INC (to 2017-06-29); GENEMAX CORP (to 2007-06-28); EDUVERSE COM (to 2002-06-17)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. Listed shows no prices and gives no investment advice.